Literature DB >> 6978365

In vitro complement activation by intercellular antibodies.

T Hashimoto, M Sugiura, S Kurihara, T Nishikawa.   

Abstract

By in vitro complement immunofluorescence, 6 sera from pemphigus with intercellular antibodies were tested for their capability to fix C1q, C4, C3, and properdin. All 6 serum samples yielded positive reaction for C3 staining. Three serum samples gave positive staining for C1q, 5 serum samples for C4, and 3 serum samples for properdin, respectively. Substitution of C2 deficient serum as a complement source inhibited C3 and properdin staining but not positive C1q and C4 staining. These results are best explained by the concept that complement activation in vitro by intercellular antibodies occurs via the classical pathway followed by assembly of the C3 amplification mechanism.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6978365     DOI: 10.1111/1523-1747.ep12507396

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  5 in total

Review 1.  Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases.

Authors:  J R Stanley
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

2.  Complement fixation by pemphigus antibody. V. Assembly of the membrane attack complex on cultured human keratinocytes.

Authors:  P Xia; R E Jordon; W D Geoghegan
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

3.  Complement fixation by pemphigus antibody. II. Complement enhanced detachment of epidermal cells.

Authors:  S Kawana; W D Geoghegan; R E Jordon
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

Review 4.  The role of complement-derived mediators in inflammatory skin diseases.

Authors:  H Tagami
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

5.  Subclass distribution of human IgG autoantibodies in pemphigus.

Authors:  C C Jones; R G Hamilton; R E Jordon
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.